Tempus AI (NASDAQ:TEM) Stock Keeps "Buy" Rating at Needham & Company LLC

Tempus AI (NASDAQ:TEM - Get Free Report)'s stock had its "buy" rating restated by stock analysts at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC's price target indicates a potential upside of 10.62% from the company's current price.

Other analysts have also issued research reports about the company. HC Wainwright upped their target price on Tempus AI from $56.00 to $66.00 and gave the company a "buy" rating in a report on Friday, September 11th. TD Cowen reissued a "buy" rating on shares of Tempus AI in a report on Wednesday, July 15th. Piper Sandler raised Tempus AI from a "neutral" rating to an "overweight" rating and upped their target price for the company from $56.00 to $76.00 in a report on Tuesday, September 1st. Roth Capital started coverage on Tempus AI in a report on Tuesday, September 8th. They issued a "neutral" rating and a $67.00 target price on the stock. Finally, Stifel Nicolaus lowered their target price on Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a report on Monday, August 3rd. Eleven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Tempus AI currently has an average rating of "Hold" and an average price target of $72.37.

Tempus AI Price Performance

NASDAQ:TEM traded up $3.99 during trading hours on Friday, hitting $67.80. The company's stock had a trading volume of 2,938,702 shares, compared to its average volume of 6,181,841. The business's 50-day moving average is $68.93 and its two-hundred day moving average is $57.12. The company has a market capitalization of $12.23 billion, a PE ratio of -46.91 and a beta of 3.54. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. Tempus AI has a 52-week low of $40.77 and a 52-week high of $93.38.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million during the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. Tempus AI's revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.22) earnings per share. As a group, research analysts anticipate that Tempus AI will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 7,062 shares of the stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total transaction of $529,650.00. Following the sale, the chief accounting officer owned 60,804 shares of the company's stock, valued at $4,560,300. This trade represents a 10.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the sale, the chief executive officer directly owned 15,874 shares in the company, valued at approximately $1,111,180. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,280,965 shares of company stock valued at $80,397,564. 24.26% of the stock is owned by company insiders.

Institutional Trading of Tempus AI

Large investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new stake in shares of Tempus AI during the third quarter valued at $27,000. EMC Capital Management acquired a new stake in shares of Tempus AI during the second quarter valued at $29,000. Ulland Investment Advisors LLC acquired a new stake in shares of Tempus AI during the third quarter valued at $41,000. Eastern Bank acquired a new stake in shares of Tempus AI during the third quarter valued at $69,000. Finally, Whittier Trust Co. boosted its stake in shares of Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company's stock valued at $41,000 after acquiring an additional 570 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus and Bristol Myers Squibb reportedly expanded their collaboration through multi-year oncology and AI-data agreements. The arrangements could increase demand for Tempus’ clinical data, analytics, and AI tools while reinforcing its credibility with a major pharmaceutical company. Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
• Positive Sentiment: Neurology partnership with Pathos AI: Tempus announced an expanded data partnership with Pathos focused on neuroscience and neurology research. The agreement broadens Tempus beyond its core oncology exposure and may create additional opportunities to monetize its clinical datasets in drug development. Tempus AI Expands Neurology Data Partnership With Pathos
• Positive Sentiment: Validation from Pathos’ financing: Pathos raised $237 million at a valuation of approximately $3 billion and is partnering with both Bristol Myers Squibb and Tempus. The financing and high valuation provide an external signal of investor confidence in AI-driven biomedical research and could raise the strategic profile of Tempus’ platform. AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
• Neutral Sentiment: Analyst commentary continues to describe Tempus as a leading AI-biotech and emphasizes its proprietary healthcare-data advantage. However, the investment case remains dependent on converting partnerships into sustained revenue and improved profitability. Tempus AI: Less Risky Than When I Said Buy
• Negative Sentiment: The announcements do not appear to disclose the full financial terms or near-term earnings impact of the collaborations. Tempus remains loss-making, so investors may still focus on execution risk, partnership monetization, and its elevated valuation.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.